McKesson Corp. has officially cut ties with its last European outpost, closing the sale of its retail and distribution businesses in Norway to NorgesGruppen. With the deal done, the Irving-based health services giant says it can zero in on its core growth plays: oncology, multispecialty, and biopharma services.
In a press release, McKesson called the transaction “the final step in McKesson’s commitment to fully exit its European operations.” The company said it will walk investors through the finer points on its fiscal third-quarter earnings call scheduled for next Wednesday, and it did not disclose the sale price in the announcement.
This is McKesson’s first announced deal of the year, and it lands as the company continues to reshape its portfolio and long-term strategy. As reported by The Dallas Business Journal, McKesson ranks among North Texas’s largest public companies and has been telegraphing a stronger tilt toward oncology under CEO Brian Tyler.
What McKesson Sold In Norway
NorgesGruppen is picking up Norsk Medisinaldepot (NMD), which includes the Vitusapotek and Ditt Apotek pharmacy chains. The deal returns a sizable share of Norway’s pharmacy network to Norwegian ownership. According to NorgesGruppen, NMD runs roughly 391 pharmacies across the country, employs more than 3,000 people, and will continue to operate as an independent subsidiary under its new owner.
Regulatory Sign-Off And Timeline
Norwegian competition authorities reviewed the transaction and signed off in December 2025, clearing the key regulatory hurdle. Regulatory disclosures on Euronext show that approval was followed by the Jan. 30 close that McKesson later announced.
Why It Matters For McKesson And Investors
Company leaders say the divestiture should free up capital and management attention so McKesson can pour more investment into oncology and multispecialty services. The financial impact of the Norway exit is slated to be detailed on the Feb. 4 earnings call, according to McKesson, and investors will be watching closely for how the company accounts for both the proceeds and the associated exit costs.
For Norway, the purchase reshapes a significant slice of the pharmacy landscape. For McKesson, it caps a long retreat from Europe and leaves the company with a cleaner, U.S.-focused portfolio. Expect plenty of fine print in upcoming filings, including any hints about operational changes for employees on either side of the Atlantic.
